ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q3 2023 Earnings Call Transcript

Page 8 of 8

A faster drug development process reduces the time it takes to bring a new drug to market. This shortened time line allows the company to generate revenue sooner and may yield benefits such as market exclusivity and patent protection. Lastly, higher pricing potential, drugs that address challenging targets or unmet needs, often command higher prices due to their unique value proposition and limited competition. This can lead to higher profit margins and increased return for the companies involved, as well as their investors. IPA is committed to enhancing the LENSai platform and utilizing cutting-edge wet-lab technologies to drive the development of more personalized, safer and targeted drugs. Our goal is to empower our partners to create best-in-class therapies, tackle on explored diseases and deliver groundbreaking solutions to patients faster by harnessing the power of true innovation and strategically deploying disruptive technologies, we aim to create significant value for our investors and position ourselves as a leader in the biotechnology industry.

Thank you for joining us this morning, and we wish each of you a pleasant rest of your day.

Operator: That does conclude today’s meeting. You may now disconnect.

Follow Immunoprecise Antibodies Ltd.

Page 8 of 8